|
|
|
|
|
by hannob
1345 days ago
|
|
They're doing an intention to treat analysis, which can be a bit confusing, but statistically makes sense and is the gold standard for clinical trials. You're basicall saying "our randomization at the beginning of the trial is key to avoid biases, so we can't reassign people from the treatment group to the other group, even if they practically don't get the treatment". The reason is if you allow people to switch, your assignment is no longer random. People who avoid the treatment may have different health properties than the ones who don't. In essence, you need your trial to be robust and large enough that a few people not getting the treatment don't matter. |
|